INDICATIONS

Heart Failure in Adult Patients
Corlanor® is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting Read More.

Heart Failure in Adult Patients
Corlanor® is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

Heart Failure in Pediatric Patients
Corlanor® is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.

This site is intended for U.S. audiences only.
Full Prescribing Information Medication Guide Important Safety Info Indications Patient Support Resource Library Visit Patient Website

For patients with stable, symptomatic chronic HF with LVEF ≤ 35% and in sinus rhythm with heart rate ≥ 70 bpm:

Corlanor® significantly reduced the relative risk of hospitalization for worsening HF or CV death by 18%1,2

(Hazard Ratio [95% CI] = 0.82 [0.75 - 0.90]; 4.2% ARR; P < 0.0001)
  • Analysis of time to first event
  • Primary composite endpoint result reflected only a reduction in the risk of hospitalization for worsening HF with no statistically significant benefit on CV death in the overall treatment population

Corlanor® reduced the relative risk of hospitalization for worsening HF1,2

Events at any time

26% reduction 26% reduction
 

Standard of Care (SOC) was a clinical regimen that included maximally tolerated doses of beta-blockers and, in most cases, ACE inhibitors or ARBs, spironolactone, and diuretics.1

The Systolic Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT) tested the effect of heart rate reduction with Corlanor® in 6,505 patients with chronic HF. Patients received Corlanor® or placebo in addition to SOC.1,2

Study randomization Study randomization

Inclusion criteria:1

  • Optimized and stable treatment for ≥ 4 weeks
  • Sinus rhythm with a resting heart rate ≥ 70 bpm
  • NYHA class II to IV
  • Reduced LVEF (≤ 35%)
  • Hospitalization due to worsening heart failure within 12 months
  • Hospitalization for worsening HF within 12 months

people icon
divider
See how elevated heart rate may affect your chronic HF patients.
divider

ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; ARR = absolute risk reduction; BPM = beats per minute; CI = confidence interval; CV = cardiovascular; HF = heart failure; HR = hazard ratio; If = pacemaker/funny current; LVEF = left ventricular fraction; mg = milligram(s); 
n = sample size; NYHA = New York Heart Association; P = p value; SOC = standard of care.

References
  1. Corlanor® [ivabradine] prescribing information, Amgen.
  2. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet. 2010;376:875-885.

IMPORTANT SAFETY INFORMATION

  • Contraindications: Corlanor® is contraindicated in patients with acute decompensated heart failure, clinically significant hypotension, sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular block (unless a functioning demand pacemaker is present), clinically significant bradycardia, severe hepatic impairment, pacemaker dependence (heart rate maintained exclusively by the pacemaker), and concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors.
  • Fetal Toxicity: Corlanor® may cause fetal toxicity when administered to a pregnant woman based on embryo-fetal toxicity and cardiac teratogenic effects observed in animal studies. Advise females of reproductive potential to use effective contraception when taking Corlanor®.
  • Atrial Fibrillation: Corlanor® increases the risk of atrial fibrillation. The rate of atrial fibrillation in patients treated with Corlanor® compared to placebo was 5% vs. 3.9% per patient-year, respectively. Regularly monitor cardiac rhythm. Discontinue Corlanor® if atrial fibrillation develops.
  • Bradycardia and Conduction Disturbances:

    • Adult Heart Failure Patients 
    Bradycardia, sinus arrest and heart block have occurred with Corlanor®. The rate of bradycardia in patients treated with Corlanor® compared to placebo was 6% (2.7% symptomatic; 3.4% asymptomatic) vs. 1.3% per patient-year, respectively. Risk factors for bradycardia include sinus node dysfunction, conduction defects, ventricular dyssynchrony, and use of other negative chronotropes. Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsades de pointes, especially in patients with risk factors such as use of QTc prolonging drugs.

    Concurrent use of verapamil or diltiazem also increases Corlanor® exposure, contributes to heart rate lowering, and should be avoided. Avoid use of Corlanor® in patients with 2nd degree atrioventricular block unless a functioning demand pacemaker is present.

    Pediatric Heart Failure Patients 
    Bradycardia and first-degree heart block were observed in pediatric patients treated with Corlanor®. Asymptomatic and symptomatic bradycardia were observed in 6.8% and 4.1% of pediatric patients treated with Corlanor®, respectively. In the placebo treatment arm, 2.4% of pediatric patients had asymptomatic bradycardia, but none had symptomatic bradycardia. Bradycardia was managed through dose titration but did not result in study drug discontinuation.

  • Adverse Reactions:

    • Adult Heart Failure Patients 
    The most common adverse drug reactions reported at least 1% more frequently with Corlanor® than placebo and that occurred in more than 1% of patients treated with Corlanor® were bradycardia (10% vs. 2.2%), hypertension or increased blood pressure (8.9% vs. 7.8%), atrial fibrillation (8.3% vs. 6.6%), and luminous phenomena (phosphenes) or visual brightness (2.8% vs. 0.5%).

    In postmarketing experience, torsades de pointes has been observed.

    Pediatric Heart Failure Patients 
    Bradycardia (symptomatic and asymptomatic) occurred at rates similar to those in adults. Phosphenes were observed in pediatric patients treated with Corlanor®.

Please see full Prescribing Information and Medication Guide.

INDICATIONS

Heart Failure in Adult Patients 
Corlanor® is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

Heart Failure in Pediatric Patients 
Corlanor® is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.

IMPORTANT SAFETY INFORMATION

  • Contraindications: Corlanor® is contraindicated in patients with acute decompensated heart failure, clinically significant hypotension, sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular block (unless a functioning demand pacemaker is present), clinically significant bradycardia, severe hepatic impairment, pacemaker dependence (heart rate maintained exclusively by the pacemaker), and concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors.
  • Fetal Toxicity: Corlanor® may cause fetal toxicity when administered to a pregnant woman based on embryo-fetal toxicity and cardiac teratogenic effects